tetano
Editor, Senior Moderator
Autoimmun Rev. 2020 May 4:102554. doi: 10.1016/j.autrev.2020.102554. [Epub ahead of print]
Convalescent plasma in Covid-19: Possible mechanisms of action.
Rojas M[SUP]1[/SUP], Rodriguez Y[SUP]2[/SUP], Monsalve DM[SUP]1[/SUP], Acosta-Ampudia Y[SUP]1[/SUP], Camacho B[SUP]3[/SUP], Gallo JE[SUP]4[/SUP], Rojas-Villarraga A[SUP]5[/SUP], Ram?rez-Santana C[SUP]1[/SUP], D?az-Coronado JC[SUP]6[/SUP], Manrique R[SUP]7[/SUP], Mantilla RD[SUP]2[/SUP], Shoenfeld Y[SUP]8[/SUP], Anaya JM[SUP]9[/SUP].
Author information
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible of the coronavirus disease 2019 (COVID-19) pandemic. Therapeutic options including antimalarials, antivirals, antibiotics and vaccines are under study. Meanwhile the current pandemic has called attention over old therapeutic tools to treat infectious diseases. Convalescent plasma (CP) constitutes the first option in the current situation, since it has been successfully used in other coronaviruses outbreaks. Herein, we discuss the possible mechanisms of action of CP and their repercussion in COVID-19 pathogenesis, including direct neutralization of the virus, control of an overactive immune system (i.e., cytokine storm, Th1/Th17 ratio, complement activation) and immunomodulation of a hypercoagulable state. All these benefits of PC are expected to be better achieved if used in non-critically hospitalized patients, in the hope of reducing morbidity and mortality.
Copyright ? 2020. Published by Elsevier B.V.
KEYWORDS:
ACE-2 receptor; COVID-19; Convalescent plasma; Coronavirus; Cytokines; Intravenous immunoglobulins; Neutralizing antibodies; SARS-Cov-2
PMID:32380316DOI:10.1016/j.autrev.2020.102554
Convalescent plasma in Covid-19: Possible mechanisms of action.
Rojas M[SUP]1[/SUP], Rodriguez Y[SUP]2[/SUP], Monsalve DM[SUP]1[/SUP], Acosta-Ampudia Y[SUP]1[/SUP], Camacho B[SUP]3[/SUP], Gallo JE[SUP]4[/SUP], Rojas-Villarraga A[SUP]5[/SUP], Ram?rez-Santana C[SUP]1[/SUP], D?az-Coronado JC[SUP]6[/SUP], Manrique R[SUP]7[/SUP], Mantilla RD[SUP]2[/SUP], Shoenfeld Y[SUP]8[/SUP], Anaya JM[SUP]9[/SUP].
Author information
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible of the coronavirus disease 2019 (COVID-19) pandemic. Therapeutic options including antimalarials, antivirals, antibiotics and vaccines are under study. Meanwhile the current pandemic has called attention over old therapeutic tools to treat infectious diseases. Convalescent plasma (CP) constitutes the first option in the current situation, since it has been successfully used in other coronaviruses outbreaks. Herein, we discuss the possible mechanisms of action of CP and their repercussion in COVID-19 pathogenesis, including direct neutralization of the virus, control of an overactive immune system (i.e., cytokine storm, Th1/Th17 ratio, complement activation) and immunomodulation of a hypercoagulable state. All these benefits of PC are expected to be better achieved if used in non-critically hospitalized patients, in the hope of reducing morbidity and mortality.
Copyright ? 2020. Published by Elsevier B.V.
KEYWORDS:
ACE-2 receptor; COVID-19; Convalescent plasma; Coronavirus; Cytokines; Intravenous immunoglobulins; Neutralizing antibodies; SARS-Cov-2
PMID:32380316DOI:10.1016/j.autrev.2020.102554